WuXi Biologics to Acquire Pfizer's Biologics Manufacturing Facilities in China
Shots:
- WuXi Biologics signs an equity agreement with Pfizer to acquire its state-of-the-art biologics manufacturing facilities along with its labor force in Hangzhou- China. The transaction is expected to close in H1’21
- The agreement will boost WuXi Biologics’ commercial DS & DP capabilities to address surging manufacturing demands
- The state-of-the-art 50-000 m2 facilities include DS capacities equipped with 2x2000L single-use bioreactors expandable to 4x2000L (MFG20) and DP capacities of vial filling (DP9) and pre-filled syringe (DP10). Wuxi will commence the production following the deal closure
Ref: PRNewswire | Image: WuXi Biologics
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com